ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3046

Venous Disease-Specific Quality-of-Life Is Impaired in Patients with Vascular Behcet’s Disease

Fatma Alibaz-Oner1, Belgin Aldag2, Mustafa Aldag3, Ali Ugur Unal4, Tayfur Toptas5, Tülin Ergun6 and Haner Direskeneli4, 1Department Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, 2Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, 3Dr.Siyami Ersek Cardiovascular Surgery Hospital,, Istanbul, Turkey, 4Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, 5Hematology, Marmara University, Istanbul, Turkey, 6Dermatology, Marmara University Faculty of Medicine, Dermatology, Istanbul, Turkey

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Behcet's syndrome, Quality of life and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Vasculitis Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Vascular involvement is seen in up to 40% of the patients with Behcet’s disease (BD), with lower extremity deep vein thrombosis (DVT) as the most frequent form of vascular involvement. Chronic post-thrombotic syndrome (CPTS) develops in up to one-half of patients with DVT and is associated with varying combinations of leg pain, oedema, hyperpigmentation and varicose collateral veins. There is no data about CPTS in DVT associated with BD. In this study,we aimed to evaluate venous disease spesific quality of life (QoL) in patients with Vascular Behçet’s Disease (VBD).

Methods: In this study, 62 patients (M/F: 47/15, mean age: 38.6±9.2 years) with VBD, who were regularly followed in Marmara University Behcet’s Clinics and 29 patients (M/F: 20/9, mean age: 41.6±11.8  years) with DVT associated with non-BD causes, who were followed in Hematology and Vascular Surgery Departments, were assessed. Mean duration after DVT was 6.7±5 years in VBD and 1.6±1 years in non-BD group. Venous Disability Score (VDS) and Venous Clinical Severity Score (VCSS) were used to evaluate the severity of venous insufficiency. Venous disease-specific QoL (the primary outcome) was measured using the Turkish validated form of Venous Insufficiency Epidemiological and Economic Study Quality of Life/Symptom questionnaire (VEINES-QoL/Sym). After calculation, VEINES-QoL and VEINES-Sym sub-scores were identified. Higher scores shows better QoL. SF-36 and Behcet Syndrome Activity Score (BSAS) questionnaires were also fullfilled for patients.

Results: VCSS and VDS were significantly worse in non-BD group compared to VBD, similarly VEINES-QoL and VEINES-Sym were significantly better in VBD group (Table 1). There were no correlations between VEINES-QoL, VEINES-Sym score and duration after DVT, daily sitting and standing times. VEINES-QoL and VEINES-Sym negatively correlated with VCSS (r: -0.367, p<0.001 and r:-0.384, p<0.001, respectively) and VDS (r: -0.288, p=0.007 and r:-0.265, p=0.013, respectively). VEINES-Sym and VEINES-QoL also significantly correlated with BSAS (r: -0.526, p<0.001 and r:-0.496, p<0.001, respectively). Physical and mental components of SF-36 were similar between VBD and non-BD groups.

Conclusion: In VBD, we observed that venous-specific QoL and symptoms worsen together with increasing VDS and VCSS scores. These results suggest that better control of disease activity may increase the QoL, as well as preventing the relapses in venous Behcet’s disease.

Table 1: Quality of life parameters in patients with Deep Vein Thrombosis associated with Behçet’s Disease and non-Behçet’s Group.

 

Non-Behcet’s group

(n=29)

Behcet’s group

(n=62)

p value

VCSS

6.5 ±4.5

4.2±4.6

0.031

VDS

1.6±0.5

0.9±0.6

0.000

MCS

40.8±10.2

44.9±9.5

0,071

PCS

40.3±9.3

43.1±10.5

0.222

VEINES-QoL

73.3±17.9

87.9 ±16.9

0.000

VEINES-Sym

32.3±9.8

39.3±9.2

0.001

VCSS: Venous Clinical Severity Score, VDS: Venous Disability Score, MCS:Mental component of SF-36,  PCS: Physical component of SF-36, VEINES-QoL/Sym: Venous Insufficiency Epidemiological and Economic Study Quality of Life/Symptom questionnaire.


Disclosure: F. Alibaz-Oner, None; B. Aldag, None; M. Aldag, None; A. U. Unal, None; T. Toptas, None; T. Ergun, None; H. Direskeneli, None.

To cite this abstract in AMA style:

Alibaz-Oner F, Aldag B, Aldag M, Unal AU, Toptas T, Ergun T, Direskeneli H. Venous Disease-Specific Quality-of-Life Is Impaired in Patients with Vascular Behcet’s Disease [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/venous-disease-specific-quality-of-life-is-impaired-in-patients-with-vascular-behcets-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/venous-disease-specific-quality-of-life-is-impaired-in-patients-with-vascular-behcets-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology